To determine the clinicohematological factors predictive for the appearance of major vascular complications (MVC) in patients with essential thrombocythemia (ET), 148 consecutive such patients were retrospectively assessed for the development of MVC during a median follow-up of 58.5 months. Seventy-seven patients had vascular risk factors, and 37 a history of MVC at ET diagnosis. Forty-nine MVC were registered in 33 patients during the follow-up period. The actuarial probability of MVC was 27% at 6 years in the whole series, 35.6% for patients above 60 years, and 21.4% for patients younger than 60 years, whereas only one of the 36 patients younger than 45 years had MVC. At multivariate analysis, age Ͼ60 years, history of major ischemia and hypercholesterolemia were the variables associated with an increased MVC risk. These results suggest that all ET patients above 60 years should be treated, whereas in younger patients treatment decisions should be primarily based on the existence of risk factors for MVC.
Introduction
Essential thrombocythemia (ET) is a chronic myeloproliferative disorder characterized by persistent thrombocytosis associated with an increased frequency of thrombotic and hemorrhagic complications. 1 Although the available studies 2 indicate a nearly normal life expectancy for ET patients, morbidity and mortality from thrombosis and bleeding are important. The increased bleeding risk has been linked to the presence of extreme thrombocytosis 3 and to the use of aspirin or other nonsteroidal antiinflammatory drugs. 4 On the contrary, the factors accounting for the appearance of thrombotic events in ET patients are not clearly established. Thus, although several risk factors, such as advanced age, 5 previous history of thrombosis 5, 6 and existence of associated vascular risk factors, 7 have been identified, there are discrepancies between the different studies. [5] [6] [7] [8] [9] [10] On the other hand, there is no universal agreement on the criteria for the selection of ET patients who need cytotoxic treatment, mainly because of the hazard associated with such a therapy. In this setting, a better knowledge of the variables associated with a higher thrombotic risk can be of help to make treatment decisions.
The primary aim of the present study was to determine the clinicohematological factors predictive for the appearance of major vascular complications in a series of 148 consecutive ET patients with a long follow-up. Correspondence 
Patients and methods

Patient population and diagnostic criteria
Between January 1979 and June 1994, 148 patients consecutively diagnosed with ET at the Hematology Department of the Hospital Clinic of Barcelona and the Hospital del Mar of Barcelona, are the subject of the present study. The diagnostic criteria for ET were those of the Polycythemia Vera Study Group, 11 which included platelet count Ͼ600 × 10 9 /l, absence of the Ph chromosome, lack of either marked bone marrow fibrosis or increased total red cell volume, and exclusion of iron deficiency or other causes of reactive thrombocytosis. In all patients the clinicohematological data at ET diagnosis were retrospectively obtained from the medical records.
Assessment of cardiovascular risk factors
Information concerning the possible existence of major risk factors for the development of vascular disease (ie arterial hypertension, cigarette smoking, hypercholesterolemia and diabetes mellitus) was obtained from the medical charts of the 148 patients. Patients with either a high blood pressure or a normal blood pressure but taking drugs and/or following a diet under physician care for arterial hypertension were considered as having arterial hypertension. 5 Patients with a fasting (overnight) venous plasma glucose concentration greater than 140 mg/dl and cholesterol concentration greater than 240 mg/dl on at least two separate occasions were diagnosed as having diabetes mellitus and hyperlipidemia, respectively. Moreover, those following a diet and/or taking drugs for controlling hyperglycemia and cholesterol plasma levels were considered, diabetic and hypercholesterolemic, respectively.
5,7
Vascular complications
The following were considered as major arterial events: 7 (1) central nervous system (CNS) complications, including transient ischemic attacks (TIA), infarctive cerebrovascular accidents (CVA) documented by computed tomography or nuclear magnetic resonance imaging, and retinal artery occlusion; (2) cardiac complications, including angina pectoris and myocardial infarction; and (3) peripheral arterial complications, including intermittent claudication of the legs and thromboembolism of the leg arteries. Microvascular circulation disturbances such as acroparesthesias, erythromelalgia and its ischemic complications, visual disturbances and atypical neurological ischemic events were not considered as severe vascular events because of the established therapeutic effect of aspirin in this platelet-dependent microvascular syndrome of essential thrombocythemia. 12, 13 Venous complications included deep-vein thrombosis of the peripheral vasculature (DVT) diagnosed by phlebography or Doppler ultrasound, and pulmonary embolism. In each patient the time lapse from diagnosis to the appearance of the first major vascular complication was recorded.
Therapy
Therapy choice was based on the physicians' best clinical judgement. It was common practice to avoid cytotoxic treatment as much as possible in younger patients unless they have had major thrombotic complications before ET diagnosis. Given the retrospective nature of the study, patients' treatment varied during the study period depending on the therapy generally recommended at the time when the patients were diagnosed. Overall, 122 patients received treatment, which included hydroxyurea (n = 66), 32 P (n = 49), busulfan (n = 6) and melphalan (n = 1). In addition, 19 patients received alfainterferon. In those patients treated, the goal was to decrease the platelet count below 400 × 10 9 /l. Antiaggregating therapy (dipyridamole, n = 40; aspirin, n = 61) was given to 101 patients.
Statistical analysis
Survival and time-to-thrombosis curves were plotted by the product-limit estimate of Kaplan and Meier 14 and statistically compared by the log-rank test. 15 The following variables, recorded at diagnosis, were analyzed for their association with thrombosis: age (above or below the series' median age), sex, presence of vascular risk factors (arterial hypertension, cigarette smoking, hypercholesterolemia, diabetes), previous ischemic events (either prior to or at ET diagnosis), presence of major vascular complications, splenomegaly, platelet count, Hb level, serum LDH and uric acid levels. Those variables attaining a significance level below 0.1 at the univariate analysis were included in a Cox proportional hazards model 16 for assessing their independent association with thrombosis. In this model, the proportional hazard assumption was checked by plotting the log-log adjusted survival curves, and the Wald's statistics was used to ascertain the significance of the correlation coefficients. The above analysis was also separately performed in the group of patients younger than 60 years and in patients older than 60 years. The BMDP was used for computations and the Graph Pad software (Graph Pad Software Inc, San Diego, CA, USA) for graphical representations.
Results
The main clinical and laboratory characteristics of the 148 patients at diagnosis are shown in Tables 1 and 2 . Eighty-five /l. Nine patients with hemorrhagic complications were registered (mean platelet count 1325 ± 146 × 10 9 /l). Twenty-six patients (17.6%) had a history of major vascular complications (MVC) prior to ET diagnosis (median time from the above complication to diagnosis 35.5 months, range: 3-204), and 18 had a major vascular event at presentation of ET. Since seven ET patients had MVC both prior to and at ET diagnosis, a total of 37 patients (25%) had 50 major vascular ischemic events at time of diagnosis of ET. The mean platelet count of these 37 patients was 956 ± 321 × 10 9 /l. With a median follow-up for the whole series of 58.5 months, 15 patients have died, of whom only two from thrombotic complications and the other two from acute nonlymphoblastic leukemia (both of them had received radioactive phosphorus). Seventy-five patients (50.7%) have remained asymptomatic through their evolutive course, whereas an additional 41 patients have had minor vascular complications and 17 patients have had hemorrhagic episodes, of which only six were major hemorrhagic events. Thirty-three patients (22.3%) developed 49 MVC during the follow-up, the most common sites being the cerebrovascular, peripheral vascular and coronary arterial territories (Table 3 ). Figure 1 shows the actuarial probability of appearance of MVC in the whole series. As can be seen, the maximum cumulative probability of major ischemic events (27%) was reached at 6 years.
At time of diagnosis, 77 patients (52%) had vascular risk factors, including arterial hypertension (n = 39), cigarette smoking (n = 34), hypercholesterolemia (n = 10), and diabetes mellitus (n = 8). There were 36 patients (30 females and six males) younger than 45 years at diagnosis. Fifteen of them had vascular risk factors: cigarette smoking (n = 15), hypercholesterolemia (n = 2), and arterial hypertension (n = 1). Only four of these younger patients had a history of MVC at ET diagnosis (CVA, two cases; TIA, one case; and deep-venous thrombosis plus pulmonary embolism, one case).
As shown in Table 4 , at the univariate analysis four variables were associated with an increased risk for developing MVC: age, history of major ischemic events, arterial hypertension and hypercholesterolemia. Table 5 shows the results of the multivariate analysis. As can be observed, only three of the above four variables maintained their predictive value for the appearance of severe vascular complications: age Ͼ60 years, history of major ischemic complications, and hypercholesterolemia. Figure 1 depicts the actuarial probability of developing a MVC according to the presence or not of the above three risk factors and adjusted for the other significant covariates. The expected probability of developing an MVC at 6 years of diagnosis was 35.6% for patients older than 60 years, and 21.4% for patients younger than 60 years. The expected probability of MVC at 6 years was 42.6% for patients with a history of major ischemia, and 59.5% for patients with hypercholesterolemia. When the analysis was restricted to patients older than 60 years, age disappeared as a prognostic factor, whereas hypercholesterolemia and history of ischemic events retained their predictive value for the development of MVC. Multivariate analysis in patients younger than 60 years showed that age (45-60 years vs Ͻ45 years), hypercholesterolemia, and history of ischemic events remained as prognostic factors for the appearance of major ischemic complications. Only one of the 36 patients younger than 45 years developed serious vascular complications along her evolutive course.
Discussion
The present study confirms a high incidence of microvascular circulation disturbances and major arterial thrombotic complications in a large series of patients with ET. 1, [4] [5] [6] [7] [8] [9] [10] [17] [18] [19] [20] The frequency of thrombotic complications at presentation of ET in the different retrospective studies varies from 31 to 83%. 1 The arterial thrombotic manifestations of ET in 809 patients from 11 retrospective studies were described as microcirculatory disturbances in 41%, of which 24% involved the extremities and 17% the cerebral circulation. Major arterial thrombotic complications occurred in 20%, but the incidence of deep venous thrombosis including hepatic, portal and splenic vein thrombosis, was as low as 4%. 1 The most frequent thrombotic complications in 148 ET patients were microvascular circulation disturbances ocurring in 29% of cases at presentation and in 27.7% during followup, followed by MVC (25% at presentation and 22.3% during long-term follow-up). The most frequent major vascular occlusive complications following ET diagnosis involved the cerebral circulation as TIAs and stroke, followed by the peripheral and coronary arteries ( Table 3 ). The factors associated with a higher risk of MVC were advanced age, history of ischemic complications and hypercholesterolemia. Thus, patients over 60 years had 3.3 times more risk for the development of ischemic complications than the remaining ones, whereas patients between 45 and 60 years were also at a higher risk of MVC than younger patients. Actually, only one patient in the latter subgroup of 36 patients had a MVC during the follow-up period. These results are in accordance with those previously reported by others investigators, 5, 9, 10 and reinforce the appropriateness of a wait-and-see approach for young ET patients, as previously recommended. 21 In our series, a history of previous vascular complications or the presence of major ischemic events at the time of ET diagnosis were also strongly linked to the risk of subsequent vascular complications, as also pointed out by others. 5, 6, 22 In addition, in the present series hypercholesterolemia was the only vascular risk factor related to the appearance of ischemic events, an association not previously reported. 5, 10 On the contrary, no predictive value was observed for other vascular risk factors, such as cigarette smoking, diabetes and arterial hypertension. In this sense, cigarette smoking has been related to a greater incidence of arterial ischemic complications in ET patients in some, 7 but not all studies, 5, 10 whereas such an association has not been observed for diabetes and hypertension. 5, 10 On the other hand, the lack of predictive value of platelet counts, in agreement with the results obtained in most Actuarial probability of appearance of major vascular complications (MVC) in 148 ET patients (a), and according to age group (b), the history or not of previous vascular complications at time of ET diagnosis (c), and the presence or absence of hypercholesterolemia (d). The dotted lines in each figure indicate the adjusted probability of developing MVC when the other significant covariates remain unchanged. studies, 6, 7, 17, 19, 20, 23 is noteworthy. Actually, both in the present study and in other series, severe thrombotic events were observed in some patients who had only moderate thrombocytosis. 10, 24, 25 The present study is in support of the general agreement that lowering the platelets with therapeutic agents would be indicated in high-risk ET patients with either major thrombotic or hemorrhagic complications or an age above 60 years. 5, 22, 26, 27 However, two questions remained to be solved in prospective clinical trials. Firstly, whether asymptomatic and young ET patients should be treated and how, taking into account the known leukemogenic effect of cytotoxic agents. 28, 29 Hydroxyurea does have leukemogenic potential, 29, 30 a very important consideration when deciding whether or not to commit symptomatic younger patients with ET to continuous long-term therapy with this drug. The therapeutic effects of interferon in the treatment of ET include the effective control of thrombocytosis, reduction of splenomegaly and the control of disease-associated symptoms 31 but, although interferon is a nonleukemogenic agent, its cost and toxicity have prevented its widespread use. 32 On the other hand, more than 90% of patients with ET respond to anagrelide regardless of previous therapy and the responses are durable with maintenance therapy, 33 although side-effects resulted in discontinuation of therapy in 16% of patients. 34 The lack of leukemogenic potential of anagrelide, if confirmed, would make this drug the treatment of choice for young high-risk ET patients with a history or manifestations of major vascular or bleeding complications as clear indications to correct the platelet count.
Finally, a second question to be answered is whether lowdose aspirin at platelet counts between 400 and 1.500 × 10 9 /l vs correction of platelet counts to normal by platelet lowering agents are equally effective in preventing minor and major thrombotic events in ET patients with symptoms or a history of TIAs, minor stroke, or myocardial infarction in the absence of vascular disease and risk factors. 1, 13, 35, 36 
